Stock analysts at StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Price Performance
Shares of NASDAQ PULM opened at $2.13 on Thursday. The company’s 50 day simple moving average is $2.09 and its 200 day simple moving average is $2.02. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $2.75. The firm has a market capitalization of $7.78 million, a P/E ratio of -0.88 and a beta of 1.00.
Pulmatrix (NASDAQ:PULM – Get Free Report) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%. The firm had revenue of $1.55 million during the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Stories
- Five stocks we like better than Pulmatrix
- The How And Why of Investing in Oil Stocks
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- The Role Economic Reports Play in a Successful Investment Strategy
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Why Invest in High-Yield Dividend Stocks?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
